{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:23:12Z","timestamp":1786980192210,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-026-06742-8","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T18:14:32Z","timestamp":1768241672000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Role of elexacaftor-tezacaftor-ivacaftor therapy on fecal elastase-1 and fat-soluble vitamins in children with cystic fibrosis"],"prefix":"10.1007","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2309-7952","authenticated-orcid":false,"given":"Sanem","family":"Eryilmaz Polat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7009-4917","authenticated-orcid":false,"given":"Sat\u0131","family":"\u00d6zkan Tabak\u00e7\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9598-5989","authenticated-orcid":false,"given":"I\u015f\u0131l","family":"Bilgi\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9858-454X","authenticated-orcid":false,"given":"\u00c7elebi","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1316-9545","authenticated-orcid":false,"given":"Hande","family":"Yeti\u015fgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1466-2369","authenticated-orcid":false,"given":"Meltem","family":"K\u00fcrt\u00fcl \u00c7akar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3897-5650","authenticated-orcid":false,"given":"Gamze","family":"Ak\u00e7a Din\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3829-1918","authenticated-orcid":false,"given":"Ayy\u00fcce","family":"Aktemur \u00dcnl\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9224-5237","authenticated-orcid":false,"given":"\u015eule Selin","family":"Akyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7301-3692","authenticated-orcid":false,"given":"Salih","family":"Uytun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6593-0143","authenticated-orcid":false,"given":"Murat Yasin","family":"Gen\u00e7o\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0334-6336","authenticated-orcid":false,"given":"Dilber","family":"Ademhan Tural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9804-1200","authenticated-orcid":false,"given":"G\u00f6k\u00e7en Dil\u015fa","family":"Tu\u011fcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6209-196X","authenticated-orcid":false,"given":"G\u00fczin","family":"Cinel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"6742_CR1","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1126\/science.2475911","volume":"245","author":"JR Riordan","year":"1989","unstructured":"Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z et al (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066\u20131073. https:\/\/doi.org\/10.1126\/science.2475911","journal-title":"Science"},{"key":"6742_CR2","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1016\/j.jcf.2017.06.011","volume":"16","author":"VK Singh","year":"2017","unstructured":"Singh VK, Schwarzenberg SJ (2017) Pancreatic insufficiency in cystic fibrosis. J Cyst Fibros 16:S70\u2013S78. https:\/\/doi.org\/10.1016\/j.jcf.2017.06.011","journal-title":"J Cyst Fibros"},{"key":"6742_CR3","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1177\/014107689809134S07","volume":"91","author":"M Wilschanski","year":"1998","unstructured":"Wilschanski M, Durie PR (1998) Pathology of pancreatic and intestinal disorders in cystic fibrosis. J R Soc Med 91:S40\u2013S49. https:\/\/doi.org\/10.1177\/014107689809134S07","journal-title":"J R Soc Med"},{"key":"6742_CR4","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ajpath.2012.04.024","volume":"181","author":"M Abu-El-Haija","year":"2012","unstructured":"Abu-El-Haija M, Ramachandran S, Meyerholz DK, Abu-El-Haija M, Griffin M, Giriyappa RL et al (2012) Pancreatic damage in fetal and newborn cystic fibrosis pigs involves the activation of inflammatory and remodeling pathways. Am J Pathol 181:499\u2013507. https:\/\/doi.org\/10.1016\/j.ajpath.2012.04.024","journal-title":"Am J Pathol"},{"key":"6742_CR5","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1097\/00005176-198400031-00011","volume":"3","author":"JM Sturgess","year":"1984","unstructured":"Sturgess JM (1984) Structural and developmental abnormalities of the exocrine pancreas in cystic fibrosis. J Pediatr Gastroenterol Nutr 3:S55\u2013S66. https:\/\/doi.org\/10.1097\/00005176-198400031-00011","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"6742_CR6","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.pcl.2017.01.010","volume":"64","author":"A Uc","year":"2017","unstructured":"Uc A, Fishman DS (2017) Pancreatic disorders. Pediatr Clin North Am 64:685\u2013706. https:\/\/doi.org\/10.1016\/j.pcl.2017.01.010","journal-title":"Pediatr Clin North Am"},{"key":"6742_CR7","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1056\/NEJM199011293232203","volume":"323","author":"E Kerem","year":"1990","unstructured":"Kerem E, Corey M, Kerem BS, Rommens J, Markiewicz D, Levison H et al (1990) The relation between genotype and phenotype in cystic fibrosis: analysis of the most common mutation (delta F508). N Engl J Med 323:1517\u20131522. https:\/\/doi.org\/10.1056\/NEJM199011293232203","journal-title":"N Engl J Med"},{"key":"6742_CR8","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3390\/children10030554","volume":"10","author":"N Kapouni","year":"2023","unstructured":"Kapouni N, Moustaki M, Douros K, Loukou I (2023) Efficacy and safety of elexacaftor-tezacaftor-ivacaftor in the treatment of cystic fibrosis: a systematic review. Children Basel 10:554. https:\/\/doi.org\/10.3390\/children10030554","journal-title":"Children Basel"},{"key":"6742_CR9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/17476348.2021.1855980","volume":"15","author":"PG Middleton","year":"2021","unstructured":"Middleton PG, Taylor-Cousar JL (2021) Development of elexacaftor-tezacaftor-ivacaftor: highly effective CFTR modulation for the majority of people with cystic fibrosis. Expert Rev Respir Med 15:723\u2013735. https:\/\/doi.org\/10.1080\/17476348.2021.1855980","journal-title":"Expert Rev Respir Med"},{"key":"6742_CR10","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","volume":"22","author":"SJ Schwarzenberg","year":"2023","unstructured":"Schwarzenberg SJ, Vu PT, Skalland M, Hoffman LR, Pope C, Gelfond D et al (2023) Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of PROMISE-GI. J Cyst Fibros 22:282\u2013289. https:\/\/doi.org\/10.1016\/j.jcf.2022.10.003","journal-title":"J Cyst Fibros"},{"key":"6742_CR11","doi-asserted-by":"publisher","unstructured":"Stephenson KG, Lingle AJ, Baumberger KA, Dellon EP, Esther CR Jr, Meier EM et al (2023) Changes in fecal elastase-1 following initiation of CFTR modulator therapy in pediatric patients with cystic fibrosis. J Cyst Fibros 22:996\u20131001. https:\/\/doi.org\/10.1016\/j.jcf.2023.09.005","DOI":"10.1016\/j.jcf.2023.09.005"},{"key":"6742_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","volume":"4","author":"JC Davies","year":"2016","unstructured":"Davies JC, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki GS et al (2016) Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2\u20135 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med 4:107\u2013115. https:\/\/doi.org\/10.1016\/S2213-2600(15)00545-7","journal-title":"Lancet Respir Med"},{"key":"6742_CR13","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jcf.2019.03.009","volume":"18","author":"M Rosenfeld","year":"2019","unstructured":"Rosenfeld M, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki GS et al (2019) An open-label extension study of ivacaftor in children with cystic fibrosis and a CFTR gating mutation initiating treatment at age 2\u20135 years (KLIMB). J Cyst Fibros 18:838\u2013843. https:\/\/doi.org\/10.1016\/j.jcf.2019.03.009","journal-title":"J Cyst Fibros"},{"key":"6742_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.prrv.2020.04.003","volume":"35","author":"AL Nichols","year":"2020","unstructured":"Nichols AL, Davies JC, Jones D, Carr SB (2020) Restoration of exocrine pancreatic function in older children with cystic fibrosis on ivacaftor. Paediatr Respir Rev 35:99\u2013102. https:\/\/doi.org\/10.1016\/j.prrv.2020.04.003","journal-title":"Paediatr Respir Rev"},{"key":"6742_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","volume":"6","author":"M Rosenfeld","year":"2018","unstructured":"Rosenfeld M, Wainwright CE, Higgins M, Wang LT, McKee C, Campbell D et al (2018) Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respir Med 6:545\u2013553. https:\/\/doi.org\/10.1016\/S2213-2600(18)30202-9","journal-title":"Lancet Respir Med"},{"key":"6742_CR16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S2213-2600(18)30460-0","volume":"7","author":"JJ McNamara","year":"2019","unstructured":"McNamara JJ, McColley SA, Marigowda G, Liu F, Tian S, Owen CA et al (2019) Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2\u20135 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. Lancet Respir Med 7:325\u2013335. https:\/\/doi.org\/10.1016\/S2213-2600(18)30460-0","journal-title":"Lancet Respir Med"},{"key":"6742_CR17","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1164\/rccm.202204-0734OC","volume":"206","author":"JH Rayment","year":"2022","unstructured":"Rayment JH, Asfour F, Rosenfeld M, Higgins M, Liu L, Mascia M et al (2022) A phase 3, open-label study of lumacaftor\/ivacaftor in children aged 1 to <2 years with cystic fibrosis homozygous for F508del-CFTR. Am J Respir Crit Care Med 206:1239\u20131247. https:\/\/doi.org\/10.1164\/rccm.202204-0734OC","journal-title":"Am J Respir Crit Care Med"},{"key":"6742_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5364","volume":"10","author":"T Fuchs","year":"2022","unstructured":"Fuchs T, Appelt D, Niedermayr K, Ellemunter H (2022) Real-world clinical effectiveness of ivacaftor therapy in the first 24 months in two infants with cystic fibrosis and different gating mutations: a case report. Clin Case Rep 10:e05364. https:\/\/doi.org\/10.1002\/ccr3.5364","journal-title":"Clin Case Rep"},{"key":"6742_CR19","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2213-2600(16)30032-7","volume":"4","author":"C Howlett","year":"2016","unstructured":"Howlett C, Ronan NJ, NiChroinin M, Mullane D, Plant BJ (2016) Partial restoration of pancreatic function in a child with cystic fibrosis. Lancet Respir Med 4:e21\u2013e22. https:\/\/doi.org\/10.1016\/S2213-2600(16)30032-7","journal-title":"Lancet Respir Med"},{"key":"6742_CR20","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/ppul.24454","volume":"54","author":"JL Hamilton","year":"2019","unstructured":"Hamilton JL, Zobell JT, Robson J (2019) Pancreatic insufficiency converted to pancreatic sufficiency with ivacaftor. Pediatr Pulmonol 54:1654. https:\/\/doi.org\/10.1002\/ppul.24454","journal-title":"Pediatr Pulmonol"},{"key":"6742_CR21","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1002\/ppul.25065","volume":"55","author":"D Munce","year":"2020","unstructured":"Munce D, Lim M, Akong K (2020) Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor. Pediatr Pulmonol 55:3381\u20133383. https:\/\/doi.org\/10.1002\/ppul.25065","journal-title":"Pediatr Pulmonol"},{"key":"6742_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jcf.2006.01.005","volume":"5","author":"A Daftary","year":"2006","unstructured":"Daftary A, Acton J, Heubi J, Amin R (2006) Fecal elastase-1: utility in pancreatic function in cystic fibrosis. J Cyst Fibros 5:71\u201376. https:\/\/doi.org\/10.1016\/j.jcf.2006.01.005","journal-title":"J Cyst Fibros"},{"key":"6742_CR23","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1002\/ncp.10388","volume":"34","author":"S Sankararaman","year":"2019","unstructured":"Sankararaman S, Schindler T, Sferra TJ (2019) Management of exocrine pancreatic insufficiency in children. Nutr Clin Pract 34:S27\u2013S42. https:\/\/doi.org\/10.1002\/ncp.10388","journal-title":"Nutr Clin Pract"},{"key":"6742_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jpeds.2017.07.013","volume":"190","author":"RH Bartels","year":"2017","unstructured":"Bartels RH, Bourdon C, Potani I, Mhango B, van den Brink DA, Mponda JS et al (2017) Pancreatic enzyme replacement therapy in children with severe acute malnutrition: a randomized controlled trial. J Pediatr 190:85-92.e2. https:\/\/doi.org\/10.1016\/j.jpeds.2017.07.013","journal-title":"J Pediatr"},{"key":"6742_CR25","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/MPG.0000000000000830","volume":"61","author":"CJ Taylor","year":"2015","unstructured":"Taylor CJ, Chen K, Horvath K, Hughes D, Lowe ME, Mehta D et al (2015) ESPGHAN and NASPGHAN report on the assessment of exocrine pancreatic function and pancreatitis in children. J Pediatr Gastroenterol Nutr 61:144\u2013153. https:\/\/doi.org\/10.1097\/MPG.0000000000000830","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"6742_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12916-017-0783-y","volume":"15","author":"MR Struyvenberg","year":"2017","unstructured":"Struyvenberg MR, Martin CR, Freedman SD (2017) Practical guide to exocrine pancreatic insufficiency: breaking the myths. BMC Med 15:29. https:\/\/doi.org\/10.1186\/s12916-017-0783-y","journal-title":"BMC Med"},{"key":"6742_CR27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","volume":"17","author":"C Castellani","year":"2018","unstructured":"Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F et al (2018) ECFS best practice guidelines: the 2018 revision. J Cyst Fibros 17:153\u2013178. https:\/\/doi.org\/10.1016\/j.jcf.2018.02.006","journal-title":"J Cyst Fibros"},{"key":"6742_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","volume":"208","author":"JL Goralski","year":"2023","unstructured":"Goralski JL, Hoppe JE, Mall MA, McColley SA, McKone E, Ramsey B et al (2023) Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2\u20135 years with cystic fibrosis and at least one F508del allele. Am J Respir Crit Care Med 208:59\u201367. https:\/\/doi.org\/10.1164\/rccm.202301-0084OC","journal-title":"Am J Respir Crit Care Med"},{"key":"6742_CR29","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jpeds.2004.04.049","volume":"145","author":"D Borowitz","year":"2004","unstructured":"Borowitz D, Baker SS, Duffy L, Baker RD, Fitzpatrick L, Gyamfi J et al (2004) Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis. J Pediatr 145:322\u2013326. https:\/\/doi.org\/10.1016\/j.jpeds.2004.04.049","journal-title":"J Pediatr"},{"key":"6742_CR30","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jcf.2021.01.007","volume":"20","author":"KJ Ramos","year":"2021","unstructured":"Ramos KJ, Pilewski JM, Taylor-Cousar JL (2021) Challenges in the use of highly effective modulator treatment for cystic fibrosis. J Cyst Fibros 20:381\u2013387. https:\/\/doi.org\/10.1016\/j.jcf.2021.01.007","journal-title":"J Cyst Fibros"},{"key":"6742_CR31","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","volume":"187","author":"JC Davies","year":"2013","unstructured":"Davies JC, Wainwright CE, Canny GJ, Chilvers MA, Howenstine MS, Munck A et al (2013) Efficacy and safety of ivacaftor in patients aged 6\u201311 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 187:1219\u20131225. https:\/\/doi.org\/10.1164\/rccm.201301-0153OC","journal-title":"Am J Respir Crit Care Med"},{"key":"6742_CR32","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1164\/rccm.202008-3177OC","volume":"203","author":"JC Davies","year":"2021","unstructured":"Davies JC, Wainwright CE, Sawicki GS, Higgins MN, Campbell D, Harris C et al (2021) Ivacaftor in infants aged 4 to <12 months with cystic fibrosis and a gating mutation: results of a two-part phase 3 clinical trial. Am J Respir Crit Care Med 203:585\u2013593. https:\/\/doi.org\/10.1164\/rccm.202008-3177OC","journal-title":"Am J Respir Crit Care Med"},{"key":"6742_CR33","doi-asserted-by":"publisher","first-page":"192","DOI":"10.5863\/1551-6776-25.3.192","volume":"25","author":"K Ridley","year":"2020","unstructured":"Ridley K, Condren M (2020) Elexacaftor-tezacaftor-ivacaftor: the first triple-combination cystic fibrosis transmembrane conductance regulator modulating therapy. J Pediatr Pharmacol Ther 25:192\u2013197. https:\/\/doi.org\/10.5863\/1551-6776-25.3.192","journal-title":"J Pediatr Pharmacol Ther"},{"key":"6742_CR34","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","volume":"21","author":"MC Petersen","year":"2022","unstructured":"Petersen MC, Begnel L, Wallendorf M, Litvin M (2022) Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis. J Cyst Fibros 21:265\u2013271. https:\/\/doi.org\/10.1016\/j.jcf.2021.11.012","journal-title":"J Cyst Fibros"},{"key":"6742_CR35","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E et al (2019) Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 394:1940\u20131948. https:\/\/doi.org\/10.1016\/S0140-6736(19)32597-8","journal-title":"Lancet"},{"key":"6742_CR36","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P, Lands LC, McKone EF, Polineni D et al (2019) Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 381:1809\u20131819. https:\/\/doi.org\/10.1056\/NEJMoa1908639","journal-title":"N Engl J Med"},{"key":"6742_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ph15050606","volume":"15","author":"G Migliorisi","year":"2022","unstructured":"Migliorisi G, Collura M, Ficili F, Pensabene T, Bongiorno D, Collura A et al (2022) Elexacaftor-tezacaftor-ivacaftor as a final frontier in the treatment of cystic fibrosis: definition of the clinical and microbiological implications in a case-control study. Pharmaceuticals (Basel) 15:606. https:\/\/doi.org\/10.3390\/ph15050606","journal-title":"Pharmaceuticals (Basel)"},{"key":"6742_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1207356","volume":"14","author":"JG Mainz","year":"2023","unstructured":"Mainz JG, Zagoya C, Polte L, Naehrlich L, Sasse L, Eickmeier O et al (2023) Corrigendum: elexacaftor-tezacaftor-ivacaftor treatment reduces abdominal symptoms in cystic fibrosis early results obtained with the CF-specific CFAbd-Score. Front Pharmacol 14:1207356. https:\/\/doi.org\/10.3389\/fphar.2023.1207356","journal-title":"Front Pharmacol"},{"key":"6742_CR39","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0022-3476(82)80501-5","volume":"100","author":"K Gaskin","year":"1982","unstructured":"Gaskin K, Gurwitz D, Durie P, Corey M, Levison H, Forstner G (1982) Improved respiratory prognosis in patients with cystic fibrosis with normal fat absorption. J Pediatr 100:857\u2013862. https:\/\/doi.org\/10.1016\/S0022-3476(82)80501-5","journal-title":"J Pediatr"},{"key":"6742_CR40","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/j.1552-4604.1994.tb03981.x","volume":"34","author":"M Kraisinger","year":"1994","unstructured":"Kraisinger M, Hochhaus G, Stecenko A, Bowser E, Hendeles L (1994) Clinical pharmacology of pancreatic enzymes in patients with cystic fibrosis and in vitro performance of microencapsulated formulations. J Clin Pharmacol 34:158\u2013166. https:\/\/doi.org\/10.1002\/j.1552-4604.1994.tb03981.x","journal-title":"J Clin Pharmacol"},{"key":"6742_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10030483","volume":"10","author":"O Sommerburg","year":"2021","unstructured":"Sommerburg O, H\u00e4mmerling S, Schneider SP, Okun J, Langhans CD, Leutz-Schmidt P et al (2021) CFTR modulator therapy with lumacaftor\/ivacaftor alters plasma concentrations of lipid-soluble vitamins A and E in patients with cystic fibrosis. Antioxidants 10:483. https:\/\/doi.org\/10.3390\/antiox10030483","journal-title":"Antioxidants"},{"key":"6742_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/children10020252","volume":"10","author":"M Francalanci","year":"2023","unstructured":"Francalanci M, Terlizzi V, Fevola C, Di Rosa G, Pierattini V, Roselli E et al (2023) Nutritional status and circulating levels of fat-soluble vitamins in cystic fibrosis patients: a cohort study and evaluation of the effect of CFTR modulators. Children 10:252. https:\/\/doi.org\/10.3390\/children10020252","journal-title":"Children"},{"key":"6742_CR43","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1513\/AnnalsATS.202101-057OC","volume":"19","author":"DM Beswick","year":"2022","unstructured":"Beswick DM, Humphries SM, Balkissoon CD, Strand M, Vladar EK, Lynch DA et al (2022) Impact of cystic fibrosis transmembrane conductance regulator therapy on chronic rhinosinusitis and health status: deep learning CT analysis and patient-reported outcomes. Ann Am Thorac Soc 19:12\u201319. https:\/\/doi.org\/10.1513\/AnnalsATS.202101-057OC","journal-title":"Ann Am Thorac Soc"},{"key":"6742_CR44","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","volume":"377","author":"SM Rowe","year":"2017","unstructured":"Rowe SM, Daines C, Ringshausen FC, Kerem E, Wilson J, Tullis E et al (2017) Tezacaftor\u2013ivacaftor in residual-function heterozygotes with cystic fibrosis. N Engl J Med 377:2024\u20132035. https:\/\/doi.org\/10.1056\/NEJMoa1709847","journal-title":"N Engl J Med"},{"key":"6742_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2024.100551","volume":"65","author":"L Teng","year":"2024","unstructured":"Teng L, Dedousis N, Adeshirlarijaney A, Kanshana JS, Liu M, Hodges CA et al (2024) Impaired intestinal free fatty acid transport followed by chylomicron malformation, not pancreatic insufficiency, cause metabolic defects in cystic fibrosis. J Lipid Res 65:100551. https:\/\/doi.org\/10.1016\/j.jlr.2024.100551","journal-title":"J Lipid Res"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-06742-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-026-06742-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-06742-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:23:14Z","timestamp":1772551394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-026-06742-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["6742"],"URL":"https:\/\/doi.org\/10.1007\/s00431-026-06742-8","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board (Ethics Committee) of Ankara Bilkent City Hospital (Approval No: TABED-1\u201324-385). Preliminary results of this study were presented as a poster (P313) at the 48th European Cystic Fibrosis Conference, 4\u20137 June 2025, Milan, Italy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors gave consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}